Stephen P Juraschek, MD, PhD, FAHA, AHSCP-CHS
spjuraschek.bsky.social
Internist, hypertension specialist, epidemiologist, and trialist interest in healthy food access, sodium, heart disease, blood pressure regulation, and gout
👤 Joined on 14 November 2024
954
Followers
443
Following
481
Total Posts
📜 Kullanıcı Geçmişi
- 14 Kas 2024, 16:55
🎉 Bluesky'e katıldı - İlk kullanıcı adı:
@spjuraschek.bsky.social
🚫 Blokladığı Kullanıcılar
❤️ Beğendiği Gönderiler
#HotOffThePress Effects of Anti-Hypertensive Agents on Orthostatic Changes: Secondary Analysis of the Treatment of Mild Hypertension Study (TOMHS) academic.oup.com/ajh/advance-...
Show Post
We have more ways to measure blood pressure than ever before but not necessarily more confidence in what those measurements mean. Our NHLBI workshop report in @jaccjournals.bsky.social chaired w/ @spjuraschek.bsky.social provides an implementation roadmap. www.sciencedirect.com/science/arti...
Show Post
Terrific to learn from and work with you @spjuraschek.bsky.social and so many of the fantastic #Hypertension folks out there #BloodPressure #LifeSpan www.sciencedirect.com/science/arti...
Show Post
Interesting paper - Factors Associated With Discussing High Blood Pressure Readings in Clinical Notes. Naturally, nephrology, transplant, internal med are discussing the most (it's part of the job). ID, endocrine, sports medicine and GI > than cardiology? pubmed.ncbi.nlm.nih.gov/39661402/
Show Post
Huge fan of spiro, but wouldn’t use it first-line if I didn’t suspect hyperaldosteronism. No CVD outcome data and the side effects for men are not trivial. Don’t feel that the modest effect on BP in primary HTN justifies its use over A/C/D.
Show Post